Compare SMX Security Matters plc (SMX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs TG Therapeutics Inc — how do they compare? SMX Security Matters plc trades at $19.76 (market cap $16.38M), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 504.3× SMX Security Matters plc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| SMX | TGTX | |
|---|---|---|
Market Cap | $16.38M | $8.26B |
Sector | Technology | Health |
52-Week High | $295.56K | $59.06 |
52-Week Low | $12.87 | $26.39 |
Enterprise Value | $13.35M | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX trades at $17.66, up 6.9% today, with a bullish technical signal supported by strong ADX readings. The stock shows negative profitability metrics, including a -2,216.26% ROE, but recent news highlights balance sheet strengthening and commercialization progress in recycled plastics traceability.
The outlook hinges on execution of its circular economy platform amid regulatory tailwinds, but high financial losses and recent reverse stock splits signal substantial risk. Investor sentiment is cautiously optimistic due to policy-driven demand growth.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
